Specialty Drug Approvals: 2015 Highlights + 2016 Projections
In 2015, the recent trend continued with a greater-than-average number of drug approvals compared to past years. Special FDA designations such as breakthrough, fast track, orphan, accelerated approval and priority review have been applied to promising drugs or those that treat diseases with an unmet medical need. These designations have reduced the time needed for clinical trials and/or reduced the FDA review timeline, allowing pipeline products to come to market more quickly than in the past.1
Sign up to read our White Paper and receive helpful updates from Diplomat.
1. Developing products for rare disease & conditions. U.S. Food and Drug Administration (FDA) Website. Accessed December 1, 2015.
@DiplomatRxDiplomat to Dispense KEVZARA® for Treatment of Rheumatoid Arthritis https://t.co/UP9tqHvJwM11 hours ago
@SpecialtyPTimesRT @SpecialtyPTimes: How Can Independent Specialty Pharmacies Best Manage #DIR Fees? https://t.co/YXUvImlfa1 @DiplomatRx https://t.co/zbIjv…1 day ago
@DiplomatRxRichard & William both had hepatitis C—a condition neither thought he could develop. #hepatitisawareness… https://t.co/Me19c7U3RP1 day ago
@DiplomatRxDiplomat Recognized as Economic Bright Spot by Corp! Magazine https://t.co/3lNVkIbazl2 days ago
@BeBrightPinkRT @BeBrightPink: We created an interactive 5-question quiz to help u test ur knowledge on breast/ovarian cancer genetic testing ➡️ https:/…2 days ago